Earnings
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
Aptose Shareholders Approve C$2.41 Hanmi Buyout as Clinical Data Validates Triplet Strategy
Executive Summary
- The March 31, 2026 release confirms that 91.48% of voting shareholders approved the plan of arrangement for Hanmi Pharmaceutical’s subsidiary to acquire all remaining Aptose common shares at C$2.41 per share.
- The Court of King’s Bench of Alberta issued a final order approving the arrangement, with closing expected by late April 2026, subject only to customary conditions.
- FY2025 unaudited financials show a net loss of $25.5M, cash of $4.1M, and negative working capital of $2.86M. R&D expenses decreased to $11.3M as the company discontinued APTO-253 and focused solely on tuspetinib.
- Clinical highlights reiterate strong Phase 1/2 TUSCANY trial data: 90% CR/CRh rate for the TUS+VEN+AZA triplet, 100% response at 80mg/120mg doses, 78% MRD-negative status among responders, and no dose-limiting toxicities.
Material Impact
- The news is a procedural confirmation of a transaction announced in November 2025. The market has already priced in the C$2.41 offer, leaving minimal arbitrage upside (~2.5% spread).
- Financial deterioration (negative working capital, high burn rate) is rendered irrelevant for public shareholders, as Hanmi assumes funding responsibility post-closing.
- The clinical data, while scientifically robust, no longer serves as a standalone equity catalyst because the company is exiting public markets. The data primarily validates Hanmi’s strategic rationale for the acquisition.
- No new material information alters the investment thesis. The stock will trade in a tight range below C$2.41 until the deal closes, reflecting minor time-value and customary closing risk.
APS · Price
Company Overview
- Aptose Biosciences is a clinical-stage biotechnology company focused on developing targeted therapies for acute myeloid leukemia (AML).
- Flagship project: Tuspetinib (TUS), a multi-kinase inhibitor targeting FLT3, KIT, SYK, JAK, and RSK2 pathways.
- Development strategy shifted exclusively to the TUSCANY Phase 1/2 trial evaluating TUS combined with venetoclax and azacitidine (VEN+AZA) as a frontline triplet therapy for newly diagnosed AML patients ineligible for intensive chemotherapy.
- Secondary programs (APTO-253, luxeptinib) were discontinued to conserve capital and streamline operations ahead of the Hanmi acquisition.
More from APTOSE BIOSCIENCES INC.
Jun 30, 2026 · 19:32